시장보고서
상품코드
1309443

세계의 섬유근육통 치료 시장 규모, 점유율, 산업 동향 분석 리포트 : 약제 클래스별, 유통 채널별, 지역별 전망과 예측(2023-2030년)

Global Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 173 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

섬유근육통 치료 시장 규모는 2030년까지 40억 달러에 달하며, 예측 기간 중 CAGR 4.4%의 시장 성장률로 상승할 것으로 예측됩니다.

만성 섬유근육통은 환자의 일반적인 사회 및 직업 활동을 크게 제한하고 친구, 가족 및 동료와의 관계 유지에 어려움을 겪게 합니다. 모든 유형의 통증, 피로, 수면장애 및 우울증 증상은 사용 가능한 약물로 완전히 구상할 수 없습니다. 섬유근육통에 대한 더 나은 더 효과적인 치료법에 대한 요구가 높아짐에 따라 제약회사들은 연구개발 노력을 지속하고 시장을 주도하게 될 것입니다. 루푸스는 흔한(만성) 자가 면역 질환으로 다양한 신체 시스템을 약화시키고 영향을 미칠 수 있습니다. 루푸스는 일반적으로 감염과 질병으로부터 신체를 방어하는 데 도움이 되는 면역 체계가 해당 조직을 표적으로 삼아 발병합니다. 이에 따라 루푸스 환자 수와 함께 유병률도 증가하여 섬유근육통 치료 옵션에 대한 수요를 촉진하고 시장 확대의 원동력이 될 것으로 예상됩니다.

그러나 섬유근육통은 부작용이 없으면서도 많은 장점이 있는 비약물 대체요법으로 관리할 수 있습니다. 그 중 하나가 스트레스 관리입니다. 이는 과로와 정서적 긴장을 예방하거나 완화하는 전략을 세우고 매일 휴식 시간을 확보함으로써 효과를 발휘할 수 있습니다. 이는 예상 기간 중 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다. 미국 국립생물공학정보센터(NCBI)의 연구에 따르면 섬유근육통은 COVID-19에서 회복된 사람들 사이에서 널리 퍼져 있는 것으로 보고되었습니다. 이 데이터는 섬유근육통이 COVID-19에 감염된 사람들에게서 많이 나타나며, 팬데믹 이후 치료의 필요성이 높아질 수 있음을 시사합니다. 따라서 전염병으로 인해 시장이 감소했지만 이후 FM 사례 증가로 시장이 회복되기 시작했습니다.

약물 등급 전망

약물 유형에 따라 시장은 항우울제, 항경련제, 근이완제, 기타로 구분됩니다. 항우울제 부문은 2022년 시장에서 상당한 매출 점유율을 차지했습니다. 이는 섬유근육통 환자가 쉽게 이용할 수 있는 여러 가지 항우울제 옵션이 있기 때문입니다. 다양한 항우울제를 쉽게 구할 수 있으므로 처방의 유연성이 높아져 각 환자가 적절한 치료를 받을 가능성이 높아집니다. 섬유근육통 환자에게 사용하도록 승인된 항우울제 제네릭 의약품이 출시되면서 시장 확대에 힘을 보탤 것으로 예상됩니다.

유통 채널의 전망

유통 채널별로 보면 병원 약국, 약국 및 소매 약국, 온라인 프로바이더로 나뉘며, 2022년에는 약국 및 소매 약국이 가장 큰 시장 규모를 형성할 것으로 예상됩니다. 이 부문의 성장은 약국 및 소매 약국이 다양한 지역과 지역 사회의 여러 장소에 존재하고 일반 대중이 쉽게 접근할 수 있으므로 이 부문의 성장에 기인합니다. 이러한 약국들의 존재는 섬유근육통 환자들이 약물과 치료법에 쉽게 접근할 수 있도록 돕습니다.

지역 전망

지역별로 보면 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다. 북미는 2022년 시장에서 가장 높은 매출 점유율을 기록했습니다. 이는 섬유근육통의 유병률 증가, 새로운 치료 옵션, 의료 인프라 지원 등 여러 변수에 기인합니다. 중요한 의료 인프라, 높은 구매력, 섬유근육통 치료제의 수용 확대는 시장 확대에 박차를 가할 것으로 예상됩니다. 또한 이 지역 시장은 다수의 선도적인 기업과 이들이 효과적인 제품을 생산하기 위해 사용하는 제조 기술의 신흥 시장 개척에 의해 주도되고 있습니다.

목차

제1장 시장 범위와 조사 방법

  • 시장의 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 개요

  • 서론
    • 개요
      • 시장 구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 촉진요인
    • 시장 억제요인

제3장 세계의 섬유근육통 치료 시장 : 약제 클래스별

  • 세계의 항경련약 시장 : 지역별
  • 세계의 항우울제 시장 : 지역별
  • 세계의 근이완약 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제4장 세계의 섬유근육통 치료 시장 : 유통 채널별

  • 세계의 드러그스토어·소매 약국 시장 : 지역별
  • 세계의 병원 약국 시장 : 지역별
  • 세계의 온라인 프로바이더 시장 : 지역별

제5장 세계의 섬유근육통 치료 시장 : 지역별

  • 북미
    • 북미의 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미 지역
  • 유럽
    • 유럽의 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽 지역
  • 아시아태평양
    • 아시아태평양의 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카·중동 및 아프리카
    • 라틴아메리카·중동 및 아프리카의 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트
      • 사우디아라비아
      • 남아프리카공화국
      • 나이지리아
      • 기타 라틴아메리카·중동 및 아프리카

제6장 기업 개요

  • Abbott Laboratories
  • AbbVie, Inc
  • Novartis AG
  • Eli Lilly And Company
  • Amneal Pharmaceuticals, Inc
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
  • Lupin Limited
  • Viatris, Inc
  • Sun Pharmaceutical Industries Ltd
KSA 23.08.18

The Global Fibromyalgia Treatment Market size is expected to reach $4 billion by 2030, rising at a market growth of 4.4% CAGR during the forecast period.

Muscle Relaxants are widely utilized by people to ease muscle stiffness or spasms and help in relaxing painful knots. As road accidents are increasing, the usage of muscle relaxant is increasing. Therefore, Muscle relaxants accounted for $202.3 million revenue in 2022. Road traffic accidents kill approximately 1.3 million people annually and injure between 20 and 50 million others, as stated by the WHO report. Over fifty percent of road traffic deaths and injuries involve vulnerable road users, such as pedestrians, motorcyclists, cyclists, and passengers. Children and young adults aged 5 to 29 are disproportionately susceptible to road traffic injuries.

Among people of this age, it is the most common cause of death. Males under 25 are more likely than females to be involved in traffic incidents. According to statistics, males account for 73% of the traffic fatalities in this age group. 93% of road traffic fatalities occur in low- and middle-income countries, increasing road traffic injury rates in developing nations. Consequently, the rise in road accidents due to various factors is anticipated to increase the cases of fibromyalgia, which will raise the need for fibromyalgia treatment, thereby driving market expansion. Some of the factors impacting the market are research for novel drugs and possible uses of combination therapy, Co-relation between lupus and fibromyalgia, and non-drug alternative.

Chronic fibromyalgia substantially limits patients' ability to engage in typical social and professional activities and makes maintaining relationships with friends, family, and coworkers difficult. The full spectrum of pain, tiredness, sleep disturbances, and depression symptoms cannot be fully addressed by any available medicines. The growing need for better and more effective treatment options for FM will spur pharmaceutical companies to continue their research and development efforts, driving the market. Lupus is a common (chronic) autoimmune disorder that can be debilitating and has the potential to affect a variety of body systems. Lupus is developed when the immune system, which typically aids in defending the body against infection and disease, targets its tissues. As a result, it is anticipated that their prevalence will rise along with the number of lupus cases, fueling demand for fibromyalgia treatment options and fueling market expansion.

However, Fibromyalgia can be managed with non-drug alternatives with many benefits while incurring no side effects. One such alternative is stress management. This works by creating a strategy to prevent or reduce overexertion and emotional tension and allowing oneself daily relaxation time. This is expected to hamper the market growth in the projected period. Fibromyalgia is reportedly widespread among those who have recovered from COVID-19, according to a study from the National Center for Biotechnology Information (NCBI). This data suggests that fibromyalgia may be more common among those who have had COVID-19, increasing the need for treatment after the pandemic. Hence, the pandemic caused the market to decline, but later, the market started to recover due to the growing number of FM cases.

Drug Class Outlook

Based on drug class, the market is segmented into antidepressants, anticonvulsants, muscle relaxants and others. The antidepressants segment acquired a substantial revenue share in the market in 2022. This is because there are several antidepressant choices accessible for fibromyalgia patients. Multiple antidepressants are readily available, allowing for greater prescribing flexibility and a greater chance that each patient will receive the right treatment. This market's expansion is also anticipated to be aided by the availability of generic versions of antidepressants approved for use in fibromyalgia patients.

Distribution Channel Outlook

On the basis of distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies segment witnessed the largest revenue share in the market in 2022. The segment growth is due to the presence of drug stores and retail pharmacies in multiple locations in diverse neighborhoods and communities, which are extensively accessible to the general public. This ubiquitous presence guarantees easy access to drugs and treatments for those with fibromyalgia.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. This is due to several variables, including increased fibromyalgia prevalence, new treatment choices, and supporting healthcare infrastructure. A vital healthcare infrastructure, high purchasing power, and increased acceptance of fibromyalgia drugs are anticipated to fuel market expansion. The market in this region is also driven by numerous significant players and developments in manufacturing technology these businesses use to manufacture effective goods.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Anticonvulsants
  • Antidepressants
  • Muscle Relaxants
  • Others

By Distribution Channel

  • Drug stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AbbVie, Inc.
  • Novartis AG
  • Eli Lilly And Company
  • Amneal Pharmaceuticals, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Lupin Limited
  • Abbott Laboratories
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Fibromyalgia Treatment Market, by Drug Class
    • 1.4.2 Global Fibromyalgia Treatment Market, by Distribution Channel
    • 1.4.3 Global Fibromyalgia Treatment Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Fibromyalgia Treatment Market by Drug Class

  • 3.1 Global Anticonvulsants Market by Region
  • 3.2 Global Antidepressants Market by Region
  • 3.3 Global Muscle Relaxants Market by Region
  • 3.4 Global Others Market by Region

Chapter 4. Global Fibromyalgia Treatment Market by Distribution Channel

  • 4.1 Global Drug stores & Retail Pharmacies Market by Region
  • 4.2 Global Hospital Pharmacies Market by Region
  • 4.3 Global Online Providers Market by Region

Chapter 5. Global Fibromyalgia Treatment Market by Region

  • 5.1 North America Fibromyalgia Treatment Market
    • 5.1.1 North America Fibromyalgia Treatment Market by Drug Class
      • 5.1.1.1 North America Anticonvulsants Market by Country
      • 5.1.1.2 North America Antidepressants Market by Country
      • 5.1.1.3 North America Muscle Relaxants Market by Country
      • 5.1.1.4 North America Others Market by Country
    • 5.1.2 North America Fibromyalgia Treatment Market by Distribution Channel
      • 5.1.2.1 North America Drug stores & Retail Pharmacies Market by Country
      • 5.1.2.2 North America Hospital Pharmacies Market by Country
      • 5.1.2.3 North America Online Providers Market by Country
    • 5.1.3 North America Fibromyalgia Treatment Market by Country
      • 5.1.3.1 US Fibromyalgia Treatment Market
        • 5.1.3.1.1 US Fibromyalgia Treatment Market by Drug Class
        • 5.1.3.1.2 US Fibromyalgia Treatment Market by Distribution Channel
      • 5.1.3.2 Canada Fibromyalgia Treatment Market
        • 5.1.3.2.1 Canada Fibromyalgia Treatment Market by Drug Class
        • 5.1.3.2.2 Canada Fibromyalgia Treatment Market by Distribution Channel
      • 5.1.3.3 Mexico Fibromyalgia Treatment Market
        • 5.1.3.3.1 Mexico Fibromyalgia Treatment Market by Drug Class
        • 5.1.3.3.2 Mexico Fibromyalgia Treatment Market by Distribution Channel
      • 5.1.3.4 Rest of North America Fibromyalgia Treatment Market
        • 5.1.3.4.1 Rest of North America Fibromyalgia Treatment Market by Drug Class
        • 5.1.3.4.2 Rest of North America Fibromyalgia Treatment Market by Distribution Channel
  • 5.2 Europe Fibromyalgia Treatment Market
    • 5.2.1 Europe Fibromyalgia Treatment Market by Drug Class
      • 5.2.1.1 Europe Anticonvulsants Market by Country
      • 5.2.1.2 Europe Antidepressants Market by Country
      • 5.2.1.3 Europe Muscle Relaxants Market by Country
      • 5.2.1.4 Europe Others Market by Country
    • 5.2.2 Europe Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.2.1 Europe Drug stores & Retail Pharmacies Market by Country
      • 5.2.2.2 Europe Hospital Pharmacies Market by Country
      • 5.2.2.3 Europe Online Providers Market by Country
    • 5.2.3 Europe Fibromyalgia Treatment Market by Country
      • 5.2.3.1 Germany Fibromyalgia Treatment Market
        • 5.2.3.1.1 Germany Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.1.2 Germany Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.2 UK Fibromyalgia Treatment Market
        • 5.2.3.2.1 UK Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.2.2 UK Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.3 France Fibromyalgia Treatment Market
        • 5.2.3.3.1 France Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.3.2 France Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.4 Russia Fibromyalgia Treatment Market
        • 5.2.3.4.1 Russia Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.4.2 Russia Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.5 Spain Fibromyalgia Treatment Market
        • 5.2.3.5.1 Spain Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.5.2 Spain Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.6 Italy Fibromyalgia Treatment Market
        • 5.2.3.6.1 Italy Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.6.2 Italy Fibromyalgia Treatment Market by Distribution Channel
      • 5.2.3.7 Rest of Europe Fibromyalgia Treatment Market
        • 5.2.3.7.1 Rest of Europe Fibromyalgia Treatment Market by Drug Class
        • 5.2.3.7.2 Rest of Europe Fibromyalgia Treatment Market by Distribution Channel
  • 5.3 Asia Pacific Fibromyalgia Treatment Market
    • 5.3.1 Asia Pacific Fibromyalgia Treatment Market by Drug Class
      • 5.3.1.1 Asia Pacific Anticonvulsants Market by Country
      • 5.3.1.2 Asia Pacific Antidepressants Market by Country
      • 5.3.1.3 Asia Pacific Muscle Relaxants Market by Country
      • 5.3.1.4 Asia Pacific Others Market by Country
    • 5.3.2 Asia Pacific Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.2.1 Asia Pacific Drug stores & Retail Pharmacies Market by Country
      • 5.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
      • 5.3.2.3 Asia Pacific Online Providers Market by Country
    • 5.3.3 Asia Pacific Fibromyalgia Treatment Market by Country
      • 5.3.3.1 China Fibromyalgia Treatment Market
        • 5.3.3.1.1 China Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.1.2 China Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.2 Japan Fibromyalgia Treatment Market
        • 5.3.3.2.1 Japan Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.2.2 Japan Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.3 India Fibromyalgia Treatment Market
        • 5.3.3.3.1 India Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.3.2 India Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.4 South Korea Fibromyalgia Treatment Market
        • 5.3.3.4.1 South Korea Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.4.2 South Korea Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.5 Singapore Fibromyalgia Treatment Market
        • 5.3.3.5.1 Singapore Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.5.2 Singapore Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.6 Malaysia Fibromyalgia Treatment Market
        • 5.3.3.6.1 Malaysia Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.6.2 Malaysia Fibromyalgia Treatment Market by Distribution Channel
      • 5.3.3.7 Rest of Asia Pacific Fibromyalgia Treatment Market
        • 5.3.3.7.1 Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class
        • 5.3.3.7.2 Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel
  • 5.4 LAMEA Fibromyalgia Treatment Market
    • 5.4.1 LAMEA Fibromyalgia Treatment Market by Drug Class
      • 5.4.1.1 LAMEA Anticonvulsants Market by Country
      • 5.4.1.2 LAMEA Antidepressants Market by Country
      • 5.4.1.3 LAMEA Muscle Relaxants Market by Country
      • 5.4.1.4 LAMEA Others Market by Country
    • 5.4.2 LAMEA Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.2.1 LAMEA Drug stores & Retail Pharmacies Market by Country
      • 5.4.2.2 LAMEA Hospital Pharmacies Market by Country
      • 5.4.2.3 LAMEA Online Providers Market by Country
    • 5.4.3 LAMEA Fibromyalgia Treatment Market by Country
      • 5.4.3.1 Brazil Fibromyalgia Treatment Market
        • 5.4.3.1.1 Brazil Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.1.2 Brazil Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.2 Argentina Fibromyalgia Treatment Market
        • 5.4.3.2.1 Argentina Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.2.2 Argentina Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.3 UAE Fibromyalgia Treatment Market
        • 5.4.3.3.1 UAE Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.3.2 UAE Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.4 Saudi Arabia Fibromyalgia Treatment Market
        • 5.4.3.4.1 Saudi Arabia Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.4.2 Saudi Arabia Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.5 South Africa Fibromyalgia Treatment Market
        • 5.4.3.5.1 South Africa Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.5.2 South Africa Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.6 Nigeria Fibromyalgia Treatment Market
        • 5.4.3.6.1 Nigeria Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.6.2 Nigeria Fibromyalgia Treatment Market by Distribution Channel
      • 5.4.3.7 Rest of LAMEA Fibromyalgia Treatment Market
        • 5.4.3.7.1 Rest of LAMEA Fibromyalgia Treatment Market by Drug Class
        • 5.4.3.7.2 Rest of LAMEA Fibromyalgia Treatment Market by Distribution Channel

Chapter 6. Company Profiles

  • 6.1 Abbott Laboratories
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 SWOT Analysis
  • 6.2 AbbVie, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Acquisition and Mergers:
  • 6.3 Novartis AG
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Acquisition and Mergers:
  • 6.4 Eli Lilly And Company
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expenses
  • 6.5 Amneal Pharmaceuticals, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental Analysis
    • 6.5.4 Research & Development Expenses
  • 6.6 Teva Pharmaceutical Industries Ltd.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Regional Analysis
    • 6.6.4 Research & Development Expenses
  • 6.7 Zydus Lifesciences Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Trials and Approvals:
  • 6.8 Lupin Limited
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Recent strategies and developments:
      • 6.8.3.1 Trials and Approvals:
  • 6.9 Viatris, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental Analysis
    • 6.9.4 Research & Development Expense
  • 6.10. Sun Pharmaceutical Industries Ltd.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expenses
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제